121247-16-3

Basic information

• Product Name: 3-Acetylmethyl-1,2-difluoro-4-nitrobenzene
• Synonyms: 3-Acetylmethyl-1,2-difluoro-4-nitrobenzene;1-(2,3-Difluoro-6-nitrophenyl)propan-2-one;2-Propanone, 1-(2,3-difluoro-6-nitrophenyl)-;1-(2,3-Difluoro-6-nitrophenyl)
• CAS NO: 121247-16-3
• Molecular Formula: C₉H₇F₂NO₃
• Molecular Weight: 215.15
• Mol File: 121247-16-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 283.4 °C at 760 mmHg
• Flash Point: 125.196 °C
• Appearance: /
• Density: 1.378 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.514
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Acetylmethyl-1,2-difluoro-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Acetylmethyl-1,2-difluoro-4-nitrobenzene(121247-16-3)
• EPA Substance Registry System: 3-Acetylmethyl-1,2-difluoro-4-nitrobenzene(121247-16-3)

Safety Data

• Hazardous Substances Data: 121247-16-3(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 25, p. 1567, 1988 DOI: 10.1002/jhet.5570250558

InChI:InChI=1/C9H7F2NO3/c1-5(13)4-6-8(12(14)15)3-2-7(10)9(6)11/h2-3H,4H2,1H3

Upstream product

• 771-69-7 2,3,4-trifluoronitrobenzene 
• 141-97-9 ethyl acetoacetate 
• 1022112-32-8 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoic acid ethyl ester 

Downstream Products

• 121247-17-4 3,4-difluoro-2-(2-hydroxypropyl)nitrobenzene 
• 288385-98-8 1-(3-benzyloxy-2-fluoro-6-nitro-phenyl)-propan-2-one 
• 288385-99-9 1-(2-fluoro-3-methoxy-6-nitrophenyl)propan-2-one 
• 649736-29-8 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 
• 649735-41-1 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol 
• 288385-88-6 4-fluoro-2-methyl-1H-indol-5-ol 
• 952490-01-6 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yl pivalate 

Relevant articles and documents

Design, synthesis and biological evaluation of O-linked indoles as VEGFR-2 kinase inhibitors (I)

Inhibition of VEGFR-2 signaling pathway has already become one of the most promising approaches for the treatment of cancer. In this study, we describe the design, synthesis, and biological evaluation of a series of O-linked indoles as potent inhibitors of VEGFR-2. Among these compounds, 18 showed significant anti-angiogenesis activities via VEGFR-2 in enzymatic proliferation assays, with IC50 value of 3.8 nmol/L. Kinase selectivity profiling revealed that 18 was a multitargeted inhibitor, and it also exhibited good potency against VEGFR-1, PDGFR-α and β.

Commercial synthesis of a pyrrolotriazine-fluoroindole intermediate to brivanib alaninate: Process development directed toward impurity control

The development of a practical, commercial process for the preparation of 4-fluoro-2-methyl-indol-5-ol and its subsequent coupling with a pyrrolotriazine to form an advanced intermediate of the oncology therapy brivanib alaninate is described. A key aspect is the multikilogram-scale preparation of the fluoroindole intermediate from trifluoronitrobenzene and the subsequent coupling while achieving impurity minimalization. As brivanib alaninate is a high-dose drug, the synthesis of highquality API with low levels of impurities is critical.

PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS

The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.